STX - SHIELD THERAPEUTICS - Share Chat

Shield Therapeutics plc is a commercial-stage pharmaceutical company listed on the London Stock Exchange’s AIM market. Its primary focus is the development and commercialisation of Accrufer® (known as Feraccru® in Europe), an innovative, non-salt-based oral iron therapy for the treatment of iron deficiency. Accrufer offers a clinically proven alternative for patients who are intolerant of or unresponsive to traditional iron supplements, with a better gastrointestinal side-effect profile.

The company is strategically focused on expanding Accrufer’s presence, particularly within the lucrative US market, where it directly commercialises the product. In other territories, Shield typically pursues licensing and partnership agreements. While still progressing towards consistent profitability, the company’s valuation largely hinges on the successful market penetration and uptake of its flagship iron therapy.